Humana reported solid full-year 2025 results with adjusted EPS of $17.14, beating initial guidance of approximately $16.25, driven by a better-than-expected insurance benefit ratio of 90.4%. However, the company issued a conservative 2026 guidance of at least $9.00 per share, reflecting a significant projected decline due to a $3.5 billion net headwind from Star ratings. Despite this earnings pressure, Humana delivered robust membership growth, adding approximately 1 million members (20% growth) during the AEP period with retention improving by over 500 basis points. Management emphasized that while individual Medicare Advantage margins are expected to be slightly below breakeven in 2026 due to the Stars headwind, they anticipate doubling these margins when normalizing for Stars, and remain committed to unlocking earnings potential by 2028 through cost transformation and clinical excellence.
| Metric | Value | Change |
|---|---|---|
| 2025 Adjusted EPS | $17.14 | Above initial guidance of ~$16.25 |
| 2026 Adjusted EPS Guidance | At least $9.00 | Significant decline YoY |
| 2025 Insurance Benefit Ratio | 90.4% | Slightly better than guidance |
| AEP Membership Growth | ~1,000,000 members (20%) | Strong growth |
| Retention Rate Improvement | >500 basis points | Year-over-Year |
| 2026 Individual MA Growth | ~25% | Projected |
| 2026 STARS Headwind | ~$3.5 Billion | Net of mitigation |
| 2026 Individual MA Margin | Slightly Below Breakeven | Normalized for Stars implies doubling |
Management is executing a strategic pivot from volume-based growth to 'quality growth,' prioritizing customer lifetime value (NPV) over market share alone. They explicitly stated they have 'moved away from past strategies built around loss leader plans' and are designing all plans to price for a sustainable margin. This is evidenced by the fact that 70% of new sales were switchers from competitors (who often have better economics) and 75% came from high-value channels, marking a 10-percentage point improvement. This shift aims to ensure that the 25% projected membership growth in 2026 fuels long-term earnings power rather than just short-term revenue.
Humana is making significant strides in capital efficiency, which is a critical enabler for their growth strategy without jeopardizing their credit rating. The company revealed that despite expecting 40% premium growth from 2024 to 2026, statutory capital requirements will increase by less than 20%. This optimization, achieved through legal entity restructuring, reinsurance refinement, and non-core asset sales, offsets over $3 billion in capital requirements. This efficiency allows them to fund the 2026 membership growth and potential M&A while maintaining a flat debt-to-cap ratio, signaling a disciplined capital deployment strategy.
The company is aggressively pursuing a multi-year cost transformation and operational efficiency program to offset the inflationary pressure of medical costs and the Stars headwind. They are targeting $1.6 to $2 billion in pretax earnings improvements by 2028 through tactical cost cutting (supplier consolidation, early retirement programs) and broader transformation efforts (outsourcing, automation). In 2026, they expect a 'significant improvement' in the consolidated operating costs ratio, driven by operating leverage from the membership growth and these efficiency initiatives, which are progressing 'as anticipated.'
Humana is adapting its clinical and operational execution to manage the massive influx of new members while recovering its Star ratings. They have shifted their proactive care programs to start earlier in the year (Q1/Q2 vs Q2/Q4 previously) and are using data to target members who have not yet cleared Star metrics. Early operational indicators are positive, with complaints to Medicare reduced year-over-year and improved transactional NPS during the January onboarding peak. This operational discipline is intended to support the goal of returning to a top-quartile (75th percentile) Stars rating by 2028, which management views as critical for margin recovery.
The most significant red flag is the dramatic projected decline in earnings for 2026, with guidance set at 'at least $9.00' compared to $17.14 in 2025. This ~50% drop is driven by a massive $3.5 billion net headwind from Star ratings in a 'bonus year' reset. Management acknowledged that individual MA margins will be 'slightly below breakeven' in 2026 after accounting for this headwind. While they argue this is temporary and driven by the Stars reset, the sheer magnitude of the earnings collapse creates substantial execution risk and investor skepticism.
The quality of the membership growth, while touted as 'high value,' carries inherent risks that could pressure margins in the short term. Management admitted that new members have a higher Medical Loss Ratio (MLR) due to lower initial risk capture (MRA) and potentially higher medical costs if they were previously unmanaged. Additionally, 30% of new sales are on contracts rated below four stars for 2026, and the cohort has higher acquisition costs. While management argues these margins will normalize over 3-5 years, the immediate impact is a drag on profitability.
The external funding environment is deteriorating, with the advance rate notice coming in below medical cost trend. CEO James Rechtin noted that 'Medicare Advantage sits at the intersection of US fiscal pressures and a program that is incredibly popular with seniors.' While management stated they will 'adapt' their benefit structure to the final rate notice, a sustained period of inadequate funding would force them to either reduce benefits (impacting competitiveness/retention) or sacrifice margins further, creating a difficult trade-off between growth and profitability.
There is a notable discrepancy between the 'normalized' margin guidance and the GAAP reality. Management emphasizes that individual MA margins would 'double' in 2026 if normalized for Stars (i.e., if 95% of members were in 4+ star plans). However, the reality is that only 45% of members are in 4+ star plans for 2026. Relying on 'normalized' figures to paint a positive picture of the underlying business can be seen as a deflection from the fact that the core business is barely breakeven in 2026, heavily relying on the CenterWell segment to be accretive to the enterprise.
Overall: Management displayed a tone of disciplined confidence mixed with heightened conservatism regarding the near-term 2026 outlook. CEO James Rechtin was steadfast in emphasizing the shift from 'loss leader' strategies to a focus on 'stable and compelling margins,' repeatedly stating the necessity to adapt to the funding environment. CFO Celeste Mellet was highly analytical and transparent, explicitly noting that the initial 2026 guidance includes a higher level of conservatism than typical to account for the dynamic environment and the significant Stars headwind.
Confidence: MEDIUM - Management expressed high confidence in their long-term strategy (2028 targets) and operational capacity to absorb growth, but acknowledged near-term risks and execution challenges regarding Stars recovery and the 2026 funding environment, necessitating a conservative guide.
At least $9.00
Approximately 25%
Slightly below breakeven (after $3.5B Stars headwind)
Approximately $3.5 billion net
Hedging & Uncertainty: Management employed frequent hedging language, particularly regarding the 2026 outlook and the Stars recovery. Phrases like 'we expect,' 'we anticipate,' and 'if and when needed' were prevalent. CFO Celeste Mellet explicitly stated, 'We always take an appropriately conservative approach to final guidance,' and noted that the 2026 guide has 'a higher level of conservatism... than typical.' This hedging serves to lower expectations for 2026, protecting against the volatility of the Stars headwind and the dynamic rate environment. CEO James Rechtin used temporal hedges regarding the rate notice, stating, 'right now, we must wait and see where the final rate notice comes in,' which deflects commitment to a specific financial outcome until the regulatory picture is clearer.
We must deliver a stable and compelling margin. - James Rechtin, CEO
The level of conservatism in our initial guide is higher than typical. - Celeste Mellet, CFO
We have moved away from past strategies built around loss leader plans. - James Rechtin, CEO
We expect our growth to be accretive in year. - James Rechtin, CEO
We will adapt to the funding environment. - James Rechtin, CEO
We are committed to not outgrowing our operational capacity. - James Rechtin, CEO
Individual MA margins are slightly below breakeven. - Celeste Mellet, CFO
We feel good about our operational progress so far. - James Rechtin, CEO
Analyst Sentiment: Analysts were highly skeptical and focused heavily on the mechanics of the margin compression and the quality of the new members. There was persistent questioning about the 'breakeven' margins in the core insurance business and the sustainability of the growth given the funding pressure.
Management Responses: Management responses were defensive but detailed, attempting to shift the focus from the 2026 earnings trough to the long-term value (LTV) of the new members and the 2028 earnings potential. They frequently used the distinction between 'normalized' margins and the GAAP impact of Stars to justify the current guidance.
Analysts pressed heavily on the 'breakeven' nature of the 2026 individual MA margins, seeking clarity on how new members could be accretive if the core business is barely profitable. Management clarified that 'enterprise accretive' includes the CenterWell segments and that new members have higher initial MLRs but better long-term run-off potential.
There was significant focus on the $3.5 billion Stars headwind, with analysts asking for specifics on the recovery path to 2028. Management provided operational details (earlier program starts, better targeting) but refused to speculate on specific thresholds or dollar benefits for 2027.
Questions regarding the 'Advance Rate Notice' and funding environment were met with a 'wait and see' approach, with management emphasizing they would 'adapt' benefits/pricing to whatever final rates are issued, highlighting the tension between fiscal pressure and member popularity.
Humana is in the midst of a painful but necessary reset. The 2026 guidance cut to $9.00 EPS, driven by a $3.5 billion Stars headwind, creates a massive near-term hurdle that the stock will likely struggle to clear until execution is proven. While the strategic shift to 'quality growth' (focusing on retention and LTV over loss leaders) and the capital efficiency improvements are positive long-term signals, the immediate outlook is clouded by breakeven core margins and a hostile funding environment. The investment thesis rests entirely on the successful execution of the Stars recovery plan and the $2B cost transformation program to hit the 2028 targets. Until the dust settles on the 2026 Stars reset and margin trajectory stabilizes, the risk/reward appears balanced, warranting a HOLD rating.
The advance rate notice came in below medical cost trend, indicating a tightening funding environment. Management acknowledged the pressure of 'US fiscal pressures' clashing with the program's popularity, forcing them to adapt benefit structures to maintain margins.
Cost trends remain elevated, with assumptions for 2026 similar to 2025 (mid-single digits medical, low double digits Rx), exacerbated by the lack of a 'doc fix' in 2026 and the inclusion of DSH (Disproportionate Share Hospital) cuts.
The 'bonus year' reset for Star ratings is creating a massive, temporary financial headwind ($3.5B) as the industry resets to a new mean, highlighting the regulatory volatility inherent in the Medicare Advantage model.